Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Patient Factors Drive Chemotherapy Decision-Making in Metastatic Pancreatic Cancer

November 24th 2025

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma

November 20th 2025

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

Dr Gonzalez-Martin on the Rationale for Targeting NaPi2b in Ovarian Cancer

November 19th 2025

Antonio Gonzalez-Martin, MD, discusses the rationale for targeting NaPi2b in ovarian cancer.

FDA Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC

November 19th 2025

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Dr Taylor on Assessing ChatGPT's Ability to Offer Specific Information in Hematologic Malignancies

November 19th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Genomic, Immune, Epigenetic Features Drive Treatment Decision-Making in High-Risk NSCLC Subtypes

November 19th 2025

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

November 18th 2025

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Dr Masserelli on the Clinical Presentation and Management of LEMS in SCLC

November 18th 2025

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

Giredestrant Becomes First Oral SERD to Show iDFS Benefit As Adjuvant Therapy in Early ER+, HER2-Negative Breast Cancer

November 18th 2025

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

FDA Grants Fast Track Designation to DPTX3186 for Gastric Cancer

November 18th 2025

DPTX3186, a first-in-class oral condensate modulator, has received FDA fast track designation in gastric cancer.

Dr Raab on Patient Enrollment and the Design of the MajesTEC-5 Trial in NDMM

November 18th 2025

Marc S. Raab, MD, details the patient characteristics and design of the phase 2 MajesTEC-5 trial evaluating teclistamab in newly diagnosed multiple myeloma.

Newer Generations, Resistance Profiling, and Toxicity Trade-offs Guide Modern TKI Selection/Use in Oncogene-Driven NSCLC

November 18th 2025

Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.

Targeted Strategies Push the Envelope for BRAF V600E–, MET Exon 14–, and KRAS G12C–Mutated Metastatic NSCLC

November 17th 2025

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

PanTRKare Approved in China as Companion Diagnostic for Entrectinib in NTRK+ Solid Tumors

November 17th 2025

PanTRKare was approved in China as a companion diagnostic to identify patients with NTRK fusion–positive solid tumors who may be eligible for entrectinib.

FDA Grants Fast Track Designation to 4A10 for Relapsed/Refractory Acute Lymphoblastic Leukemia

November 17th 2025

The FDA has granted fast track designation to 4A10 for relapsed/refractory ALL.

Dr Marron on the Evolving Role of Tarlatamab in SCLC

November 15th 2025

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Dr Bhora on How Perioperative Immunotherapy Is Reshaping the Treatment Paradigm in Resectable NSCLC

November 15th 2025

Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.